SCB104-OA

SCB104-OA is a long-acting, sustained-release microsphere formulation of **octreotide acetate** developed by **Hainan Shuangcheng Pharmaceuticals**. Octreotide is a synthetic octapeptide analogue of naturally occurring somatostatin that inhibits the secretion of various hormones, including growth hormone (GH), glucagon, and insulin. By acting as an agonist at **somatostatin receptors** (primarily SSTR2 and SSTR5), SCB104-OA suppresses the overproduction of GH and insulin-like growth factor-1 (IGF-1). The microsphere technology allows for the sustained release of the active ingredient over several weeks, typically enabling a dosing schedule of once every four weeks via intramuscular injection. It is primarily being developed for the treatment of **acromegaly** and the management of symptoms associated with functional **neuroendocrine tumors**, such as carcinoid syndrome and vasoactive intestinal peptide-secreting tumors (VIPomas).

Other names

octreotide acetate microspheresoctreotide acetate long-acting formulationSCB104-OA (long-acting)